Elan board spat - analysis

Elan, the Irish drug company, has stepped up an unusual public defence against a catalogue of alleged conflicts of interest and corporate governance failings. Andrew Jack, pharmaceuticals correspondent, analyses the interview with the under-fire chief executive Kelly Martin.